clofibrate has been researched along with Kidney Failure, Chronic in 32 studies
angiokapsul: contains clofibrate & insoitolnicotinate
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bezafibrate treatment resulted in significant decrease in the serum concentrations of triglycerides, total cholesterol and LDL-cholesterol, whereas HDL-cholesterol serum levels increased." | 2.65 | Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients. ( Grützmacher, P; Lang, W; Scheuermann, E, 1981) |
| "Clofibrate treatment was shown to concomitantly decrease the liver levels of HNF1α, HNF4α and PCSK9 mRNA, as well as serum PCSK9, TAGs and total cholesterol concentrations in CRF rats." | 1.43 | Up-regulation of Hnf1α gene expression in the liver of rats with experimentally induced chronic renal failure - A possible link between circulating PCSK9 and triacylglycerol concentrations. ( Rutkowski, B; Sucajtys-Szulc, E; Swierczynski, J; Szolkiewicz, M, 2016) |
| "As a basis for establishing dosing guidelines in order to avoid side effects due to overdosage, the concentrations of total and free non-protein bound clofibrinic acid (CA) were determined before and after the administration of a single clofibrate dose (0, 2, 6, 12, 24, 48, 72, 96h) in patients with various degrees of impaired renal function and in a control group (n = 56)." | 1.27 | Serum levels of free non-protein bound clofibrinic acid after single dosing to patients with impaired renal function of various degrees--a multicenter study. ( Graben, N; Hartmann, H; Merk, W; Nikolaus, C; Schlierf, G; Schwandt, P, 1987) |
| "It is concluded that clofibrate treatment of hyperlipidemia in uremic patients, when carefully monitored, is safe and efficacious." | 1.26 | Clofibrate treatment of hyperlipidemia in chronic renal failure. ( Boulu, R; Crosnier, J; di Giulio, S; Drüeke, T; Nicolaĭ, A; Zingraff, J, 1977) |
| " The recommended dosage of clofibrate is 1." | 1.26 | [Fat and renal failure--therapeutic aspects]. ( Heidland, A; Hörl, M; Hörl, WH, 1982) |
| " An individualized dosage of bezafibrate and repeated checks of the serum concentrations of the drug are recommended during long-term treatment of uremic patients." | 1.26 | Treatment of uremic hypertriglyceridaemia with bezafibrate. ( Anderson, P; Norbeck, HE, 1982) |
| " Eight of the patients had moderately impaired renal function, with a creatinine clearance between 20 and 40 ml/min; the mean plasma half-life of bezafibrate in them was 7." | 1.26 | Clinical pharmacokinetics of bezafibrate in patients with impaired renal function. ( Anderson, P; Norbeck, HE, 1981) |
| " The dosage reduction from the usual clofibrate dose of 14 g/week avoided toxicity and corrected the abnormalities in serum triglyceride and high density lipoprotein cholesterol levels to or toward normal." | 1.26 | Chronic clofibrate therapy in maintenance hemodialysis patients. ( Brunzell, JD; Goldberg, AB; Haas, LB; Sherrard, DJ, 1980) |
| " If such therapy is contemplated it must be cautiously instituted at low dosage and the patient monitored by regular assessment of serum C." | 1.25 | Clofibrate-induced muscle damage in patients with chronic renal failure. ( Alvarez-Ude, F; Kerr, DN; Pierides, AM, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 30 (93.75) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.13) | 29.6817 |
| 2010's | 1 (3.13) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sucajtys-Szulc, E | 1 |
| Szolkiewicz, M | 1 |
| Swierczynski, J | 1 |
| Rutkowski, B | 1 |
| Fujioka, T | 1 |
| Ueno, T | 1 |
| Matsumoto, T | 1 |
| Watanabe, H | 1 |
| Walther, A | 1 |
| Mordasini, R | 1 |
| Riesen, W | 1 |
| Robertz, GM | 1 |
| Dengler, HJ | 1 |
| Viikari, J | 1 |
| Anttila, M | 1 |
| Kasanen, A | 1 |
| Synková, J | 1 |
| Groh, J | 1 |
| Brátová, M | 1 |
| Zahradník, J | 1 |
| Jánská, D | 1 |
| Grützmacher, P | 1 |
| Scheuermann, E | 1 |
| Lang, W | 1 |
| Lacour, B | 1 |
| Di Giulio, S | 2 |
| Nicolaï, A | 2 |
| Drüeke, T | 2 |
| Debray, M | 1 |
| Boulu, RG | 1 |
| Hörl, WH | 1 |
| Hörl, M | 1 |
| Heidland, A | 1 |
| Norbeck, HE | 2 |
| Anderson, P | 2 |
| Bjornsson, TD | 1 |
| Meffin, PJ | 1 |
| Peters, FA | 1 |
| Blaschke, TF | 1 |
| Sherrard, DJ | 1 |
| Goldberg, AB | 1 |
| Haas, LB | 1 |
| Brunzell, JD | 1 |
| Jarillo, MD | 1 |
| Coca, MC | 1 |
| Díaz Rubio, C | 1 |
| Bello, I | 1 |
| Gutiérrez-Millet, V | 1 |
| Ruilope, LM | 1 |
| Rodicio, JL | 1 |
| Alvarez Ude, F | 1 |
| Pierides, AM | 1 |
| Alvarez-Ude, F | 1 |
| Kerr, DN | 1 |
| Rumpf, KW | 2 |
| Albers, R | 1 |
| Scheler, F | 2 |
| Dosa, S | 1 |
| Mallick, NP | 1 |
| Slotki, IN | 1 |
| Gabriel, R | 1 |
| Pearce, JM | 1 |
| Faed, EM | 1 |
| McQueen, EG | 1 |
| Gugler, R | 1 |
| Kürten, JW | 1 |
| Jensen, CJ | 1 |
| Klehr, U | 1 |
| Hartlapp, J | 1 |
| Boulu, R | 1 |
| Zingraff, J | 1 |
| Crosnier, J | 1 |
| Reidenberg, MM | 1 |
| Drayer, DE | 2 |
| Rieger, J | 1 |
| Doht, B | 1 |
| Ansorg, R | 1 |
| Wessels, G | 1 |
| Müller, H | 1 |
| Busch, G | 1 |
| Loew, H | 1 |
| Gibaldi, M | 1 |
| Kijima, Y | 1 |
| Sasaoka, T | 1 |
| Kanayama, M | 1 |
| Kubota, S | 1 |
| Kasiske, BL | 1 |
| O'Donnell, MP | 1 |
| Garvis, WJ | 1 |
| Keane, WF | 1 |
| Merk, W | 1 |
| Graben, N | 1 |
| Hartmann, H | 1 |
| Nikolaus, C | 1 |
| Schlierf, G | 1 |
| Schwandt, P | 1 |
| Rahn, KH | 1 |
| Radó, JP | 1 |
| Szende, L | 1 |
| Takó, J | 1 |
| Laursen, B | 1 |
| Gormsen, J | 1 |
2 reviews available for clofibrate and Kidney Failure, Chronic
| Article | Year |
|---|---|
[Dyslipidemia in renal failure].
Topics: Arteriosclerosis; Cerebrovascular Disorders; Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Coronar | 2004 |
[Pharmacotherapy in chronic kidney failure].
Topics: Anti-Bacterial Agents; Antihypertensive Agents; Cardiac Glycosides; Clofibrate; Digitoxin; Digoxin; | 1974 |
1 trial available for clofibrate and Kidney Failure, Chronic
| Article | Year |
|---|---|
Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients.
Topics: Adult; Bezafibrate; Cholesterol; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Humans; Hyper | 1981 |
29 other studies available for clofibrate and Kidney Failure, Chronic
| Article | Year |
|---|---|
Up-regulation of Hnf1α gene expression in the liver of rats with experimentally induced chronic renal failure - A possible link between circulating PCSK9 and triacylglycerol concentrations.
Topics: Actins; Animals; Apolipoprotein B-100; Body Weight; Carrier Proteins; Clofibrate; Disease Models, An | 2016 |
[Changes in serum lipoproteins in kidney diseases. Therapeutic possibilities].
Topics: Clofibrate; Dietary Fats; Energy Metabolism; Humans; Hyperlipoproteinemias; Kidney Failure, Chronic; | 1983 |
Endogenous ligand(s) decrease drug--protein binding in uremic sera: a fluorescence probe study.
Topics: Adult; Clofibrate; Clofibric Acid; Dansyl Compounds; Female; Fluorescent Dyes; Glycine; Humans; Kidn | 1983 |
The use of clofibrate in patients with renal insufficiency.
Topics: Adolescent; Adult; Aged; Blood Proteins; Clofibrate; Female; Humans; Kidney Failure, Chronic; Male; | 1983 |
[Hypolipidemic treatment in renal insufficiency].
Topics: Adolescent; Adult; Clofibrate; Female; Humans; Hyperlipidemias; Kidney Failure, Chronic; Male; Middl | 1981 |
[Study of the binding characteristics of chlorophenoxyisobutyric acid to serum proteins in chronically uremic patients : influence of dialysis and heparine (author's transl)].
Topics: Binding, Competitive; Blood Proteins; Clofibrate; Clofibric Acid; Dialysis; Heparin; Humans; In Vitr | 1982 |
[Fat and renal failure--therapeutic aspects].
Topics: Acute Kidney Injury; Animals; Bezafibrate; Carnitine; Charcoal; Clofibrate; Clofibric Acid; Humans; | 1982 |
Treatment of uremic hypertriglyceridaemia with bezafibrate.
Topics: Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipidemias; Kidney Failur | 1982 |
Clinical pharmacokinetics of bezafibrate in patients with impaired renal function.
Topics: Adult; Aged; Bezafibrate; Clofibrate; Clofibric Acid; Creatinine; Female; Humans; Hyperlipidemias; H | 1981 |
Saliva and plasma levels and plasma protein binding of clofibrinic acid in uremic patients.
Topics: Adult; Aged; Blood Proteins; Clofibrate; Clofibric Acid; Humans; Kidney Failure, Chronic; Middle Age | 1980 |
Chronic clofibrate therapy in maintenance hemodialysis patients.
Topics: Adult; Arteriosclerosis; Cholesterol; Clofibrate; Coronary Disease; Humans; Kidney Failure, Chronic; | 1980 |
[Low dose clofibrate in the treatment of hypertriglyceridemia in hemodialysis patients (author's transl)].
Topics: Adolescent; Adult; Clofibrate; Female; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Kidney F | 1980 |
Clofibrate-induced muscle damage in patients with chronic renal failure.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Butyrates; Cholesterol; Clofibrate; Creati | 1975 |
Letter: Clofibrate-induced myopathy syndrome.
Topics: Adult; Clofibrate; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hypothyroidism; Kidney | 1976 |
Letter: Acute-on-chronic renal failure precipitated by clofibrate.
Topics: Acute Kidney Injury; Adult; Clofibrate; Female; Humans; Hyperlipidemias; Kidney Failure, Chronic; Ma | 1976 |
Clofibrate-induced myopathy and neuropathy.
Topics: Adult; Clofibrate; Humans; Kidney Failure, Chronic; Male; Motor Neurons; Neuromuscular Diseases | 1976 |
Plasma half-life of clofibric acid in renal failure.
Topics: Adult; Clofibrate; Female; Half-Life; Humans; Kidney Failure, Chronic; Kinetics; Male; Middle Aged; | 1979 |
Clofibrate disposition in renal failure and acute and chronic liver disease.
Topics: Acute Disease; Adolescent; Adult; Aged; Chronic Disease; Clofibrate; Female; Half-Life; Humans; Kidn | 1979 |
Clofibrate treatment of hyperlipidemia in chronic renal failure.
Topics: Adult; Cholesterol; Clofibrate; Female; Humans; Hyperlipidemias; Kidney Failure, Chronic; Lipids; Ma | 1977 |
Drug metabolism and active drug metabolites in renal failure.
Topics: Allopurinol; Biotransformation; Clofibrate; Dose-Response Relationship, Drug; Humans; Kidney Failure | 1977 |
Drug elimination by hemofiltration.
Topics: Ampicillin; Anti-Bacterial Agents; Clofibrate; Doxycycline; Filtration; Gentamicins; Humans; Kidney | 1977 |
[Clofibrate treatment of hyperlipidemia in long-term dialysis patients].
Topics: Clofibrate; Humans; Hyperlipidemias; Kidney Failure, Chronic; Long-Term Care; Renal Dialysis | 1976 |
Drug distribution in renal failure.
Topics: Antipyrine; Clofibrate; Dose-Response Relationship, Drug; Drug Tolerance; Humans; Kidney Failure, Ch | 1977 |
Active drug metabolites and renal failure.
Topics: Acetylation; Biotransformation; Clofibrate; Humans; Kidney Failure, Chronic; Meperidine; Methyldopa; | 1977 |
Clofibrate effect on alkaline phosphatase in renal failure.
Topics: Alkaline Phosphatase; Bone and Bones; Clofibrate; Humans; Hyperlipidemias; Isoenzymes; Kidney Failur | 1977 |
Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure.
Topics: Animals; Cholesterol; Clofibrate; Clofibric Acid; Disease Models, Animal; Glomerulonephritis; Glomer | 1988 |
Serum levels of free non-protein bound clofibrinic acid after single dosing to patients with impaired renal function of various degrees--a multicenter study.
Topics: Adult; Clofibrate; Clofibric Acid; Creatinine; Female; Humans; Kidney Failure, Chronic; Kinetics; Ma | 1987 |
Drug-induced inhibition of the diuretic response to water loading in partial vasopressin responsive nephrogenic diabetes insipidus.
Topics: Adult; Carbamazepine; Clofibrate; Diabetes Insipidus; Diuresis; Female; Glomerular Filtration Rate; | 1974 |
Pharmacological enhancement and short-term stimulation of blood fibrinolytic activity.
Topics: Adolescent; Adult; Aged; Aminocaproates; Anticholesteremic Agents; Arteriosclerosis; Arthritis, Rheu | 1969 |